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ABSTRACT: The overexpression and increased activity of the serine protease Kallikrein 5 
(KLK5) is characteristic of inflammatory skin diseases such as Rosacea. The use of inhibitors of 
this enzyme - such as 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF·HCl) or 
the anti-human recombinant Kallikrein 5 (anti-KLK5) antibody - in the treatment of the disease 
has been limited due to their low bioavailability, for which their immobilization in drug delivery 
agents can contribute to making serine protease inhibitors clinically useful. In this work, we 
synthesized gold nanoparticles (GNP) coated with a mixture of hydroxyl- and carboxyl terminated 
thiolates (GNP.OH/COOH), whose carboxyl groups were used to further functionalize the 
nanoparticles with the serine protease inhibitor AEBSF·HCl either electrostatically or covalently 
(GNP.COOH AEBSF and GNP.AEBSF, respectively), or with the anti-KLK5 antibody 
(GNP.antiKLK5). The synthesized and functionalized GNP were highly water soluble, and they 
were extensively characterized using UV-VIS absorption spectroscopy, Transmission Electron 
Microscopy (TEM), Dynamic Light Scattering (DLS) and Thermogravimetric Analysis (TGA). 
GNP.OH/COOH and their subsequent functionalizations effectively inhibited KLK5 in vitro. 
Internalization of fluorophore-coated GNP.OH/COOH in human keratinocytes (HaCaT cells) 
was proven using confocal fluorescence microscopy. Cell viability assays revealed that the 
cytotoxicity of free AEBSF is importantly decreased when it is incorporated in the nanoparticles, 
either ionically (GNP.COOH AEBSF), but most importantly, covalently (GNP.AEBSF). The 
functionalized nanoparticles GNP.AEBSF and GNP.antiKLK5 inhibited intracellular KLK5 
activity in HaCaT cells and diminished secretion of IL-8 under inflammatory conditions triggered 
by TLR-2 ligands. This study points to the great potential of these GNP as a new intracellular 
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delivery strategy for both small drugs and antibodies in the treatment of skin diseases such as 
Rosacea.  
Introduction 
Rosacea is a chronic, inflammatory skin disease characterized by erythema, telangiectasia and 
papulopustules.1,2 Its etiology is not completely known yet and pharmaceutical products on the 
market commonly contain drugs that only act upon the medical symptoms.3–5 
As the first line of defense against pathogens, keratinocytes express the Toll-like receptor TLR-
2 on their cell surface and in endosomal compartments, which can be activated by external 
agents.6,7 In Rosacea patients, the overexpression of TLR-2 enhances the sensitivity to external 
agents, increasing the expression and activity of the serine protease Kallikrein-5 (KLK5).8,9 In 
addition, the proteolytic activity of KLK5 is altered in this disease, producing pro-inflammatory 
cathelicidin peptides, which in turn leads to an increased IL-8 secretion.1,6–9 An overall 
biochemical pathway was drawn according to reports,1,8–11 and is represented in Figure 1. 
Enzymatic activity of KLK5 is regulated by endogenous serine protease inhibitors (SERPINS);12 
however, in Rosacea patients, endogenous SERPINS seem not to have enough efficacy. The use 
of serine protease inhibitors as an attempt to treat Rosacea has been reported a few times,13–15 but 
the low bioavailability of some of them, such as AEBSF·HCl or the anti-KLK5 antibody, makes 
their conventional administration still limited. Therefore, the use of carriers in the administration 
of enzymatic inhibitors could help solving the problem for the regulation of KLK5 activity, helping 
to consolidate this new therapeutic strategy in Rosacea.  
Gold nanoparticles (GNP) are becoming a main interest as a platform for biomedical applications 
such as sensing and therapy, for their multiple advantages such as chemical stability, low toxicity, 
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high extinction coefficient, and capability for varying the size and the external functionalizations 
according to the reaction conditions.16–18 According to the Enhanced Permeability and Retention 
Effect (EPR effect), the nanometric size of GNP promotes their selective extravasation from blood 
vessels to the inflamed tissues, where the permeability of vessels is higher,16,19,20 as is the case of 
the skin in patients with Rosacea.2,4,5 Therefore, GNP functionalized with the appropriate drugs 
can provide a passive targeting to the skin in Rosacea patients, decreasing the dose needed to get 
an effective treatment, as compared to the administration of the drug alone.  
Also, the functionalization with chemical entities which are capable of recognizing specific 
biomolecules, such as the case of antibodies, promotes retention of the particles around the tissues 
where their recognized antigens are located, providing an active targeting. For instance, the 
formation of a complex of GNP with an anti-KLK5 antibody could increase the concentration of 
such complex at the skin. Moreover, it is known that the size of GNP, as well as their coating 
agents, greatly influence their internalization in cells. For instance, GNP coated with PEG 
molecules can be more easily internalized in cells by increasing the length of the PEG chain and 
by decreasing the particle size.21 
For these reasons, in this work PEG-coated gold nanoparticles were synthesized and 
functionalized with the well-known serine protease inhibitor AEBSF·HCl (covalently or 
electrostatically) or with the anti-KLK5 antibody. All these nanoparticles were extensively 
characterized, and their ability to be internalized in keratinocytes and to inhibit intracellular KLK5 
and IL-8 secretion was assessed. The results suggest the potential of GNP to become an efficient 
new therapeutic approach for the efficient delivery of drugs for Rosacea treatment. 
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Figure 1. Biochemical pathway of Rosacea. The activation of TLR-2 receptors by external agents 
promotes by different routes the activation of KLK5. KLK5 activity is augmented and altered in 
Rosacea patients, leading to proinflammatory cathelicidins that orchestrate the inflammatory 
response. Adapted from 1,8–11 
 
Results and discussion 
Synthesis and characterization of GNP.OH and GNP.OH/COOH gold nanoparticles 
With the aim of functionalizing gold nanoparticles with different serine protease inhibitors, our 
initial design was the synthesis of gold nanoparticles coated with one kind of thiolated-PEG 
molecules that include a terminal carboxyl group (PEG.COOH). The synthesized particles, 
GNP.COOH, showed an SPR band near λ= 515 nm using UV-VIS absorption spectroscopy. 
These particles remain in solution after centrifugation for 30 min, for which they can be considered 
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highly-water soluble. However, further functionalization with serine protease inhibitors yielded 
nanoparticles with low water solubility, making them unsuitable for biological applications, and 
which were no longer used in further experiments.  
In order to obtain highly-water soluble particles, we considered using mixed coatings by 
including as well the thiolated PEG ligand with terminal hydroxyl groups (PEG.OH) as a water 
dispersing promoter. Thus, we synthesized nanoparticles GNP.OH/COOH, comprised of a gold 
core coated with a mixture of two different types of thiolated-PEG molecules: one with a hydroxyl 
terminal group (PEG.OH), which remains unreacted and provides water solubility, and a second 
one with a carboxyl terminal group (PEG.COOH), which can be further functionalized with serine 
protease inhibitors. Also, as control particles, hydroxyl-functionalized nanoparticles (GNP.OH) 
were synthesized, comprised of a gold core coated with only one kind thiolated-PEG molecules 
(PEG.OH) with a terminal hydroxyl group. A schematic representation of these nanoparticles is 
shown in Figure 2. 
Both GNP.OH and GNP.OH/COOH also show an SPR band near λ= 515 nm as observed by 
UV-VIS absorption spectroscopy (See Supporting Information, Figure S 1). Both GNP.OH and 
GNP.OH/COOH also remain in solution after centrifugation for 30 min, for which they can be 
considered highly-water soluble as well. For this reason, centrifugation-dissolution cycles could 
not be used for purification of GNP.OH or GNP.OH/COOH. Instead, other methods were used, 
such as dialysis or filter tubes for centrifugation. GNP were preserved in a stable solution at room 
temperature for at least one year with no apparent sedimentation or aggregation.  
As estimated by UV-VIS absorption spectroscopy,22 the GNP have an average diameter ≤3 nm, 
with an extinction coefficient of 1.49x106 L mol-1 cm-1 in both cases. Therefore, by considering 
the concentration of GNP in samples and the final volume of reaction, the number of thiols per 
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nanoparticle was calculated. For instance, GNP.OH was estimated to be covered by 232 PEG.OH 
molecules per nanoparticle, and GNP.OH/COOH covered by 121 total thiol molecules (PEG.OH 
+ PEG.COOH) per nanoparticle, with a proportion of PEG.COOH to PEG.OH of 1:1.3.  
 
 
Figure 2. Schematic representation of hydroxyl functionalized gold nanoparticles (GNP.OH) as control 
(top), and mixed hydroxyl/carboxyl functionalized gold nanoparticles (GNP.OH/COOH) for further 
functionalization (bottom), in aqueous solution.  
 
 
Functionalization of gold nanoparticles  
≤
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GNP.OH/COOH were functionalized, using the carboxyl group from the particles surface, with 
different chemical entities such as the serine protease inhibitor AEBSF·HCl, linked both 
electrostatically (GNP.COOH AEBSF) (Figure 3, A) and covalently (GNP.AEBSF) (Figure 3, 
B), and the anti-KLK5 antibody covalently (GNP.antiKLK5) (Figure 3, C). All the different 
functionalized particles were highly water soluble, as they keep stable in solution after 
centrifugation for 30 min. 
 
 
Figure 3. Ionic and covalent functionalizations of GNP.OH/COOH. A) Ionic immobilization of AEBSF 
(GNP.COOH AEBSF). B) Covalent immobilization of AEBSF (GNP.AEBSF). C) Covalent 
immobilization of anti-KLK5 antibody (GNP.antiKLK5).  
 
In the case of GNP.antiKLK5, the resulting functionalized particles are of great importance as 
they could play three important roles at the same time in the treatment of Rosacea. The first role 
is the passive targeting, achieved by the nanometric size of the platform, permitting a much higher 
extravasation in inflamed tissues such as the skin in Rosacea patients, than in healthy skin. The 
 S9 
 
second role is the active targeting, which is provided by the antibody.18,23–25 As the anti-KLK5 
antibody has a high affinity for KLK5 enzyme, their specific interaction could maximize the 
retention of the GNP at the tissues with higher concentration of KLK5, which is the case of the 
epidermis, especially in patients with Rosacea 1,9,26. Finally, a third role is believed to be the 
therapeutic potential of the the antiKLK5 itself, as it could possibly have a KLK5 inhibitory 
activity.  
Characterization of optimum GNP 
UV-VIS absorption spectroscopy 
All functionalized GNP (GNP.COOH AEBSF, GNP.AEBSF and GNP.antiKLK5) were 
characterized using UV-VIS absorption spectroscopy (See Supporting Information, Figure S 1). 
They all show the characteristic SPR band at ca. λ= 520 nm as well as bands corresponding to the 
serine protease inhibitors they contain.). Results suggest a successful functionalization in all cases, 
with no evidence of aggregation.  
Microscopy 
The size, morphology and polydispersity of GNP were confirmed by Transmission Electron 
Microscopy (TEM) (Figure 4), in GNP.OH (A) and GNP.OH/COOH (B) samples. GNP.AEBSF 
(C), GNP.antiKLK5 (D) and GNP.COOH AEBSF (E) were also observed to prove that 
functionalization does not induce particle aggregation.  
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Figure 4. TEM images of different samples of gold nanoparticles. A) GNP.OH. B) 
GNP.OH/COOH. C) GNP.AEBSF. D) GNP.antiKLK5. E) GNP.COOH AEBSF. Scale bar 
represents 100 nm. 
 
For all samples observed, the size found for the majority of GNP was 1.5±0.7 nm, which also 
was the smallest size that could be detected due to the equipment resolution; the size distribution 
did not follow a typical Gaussian curve, but instead, they followed a right-tailed Fisher distribution 
(Figure 5). Histograms show that the different GNP are monodispersed, as more than 40% of the 
counts have a diameter around 1.5 nm. However, the polydispersity of GNP.OH seems to be 
slightly higher than the rest, as the percentage of particles above 4 nm in diameter is 25%, while 
in the rest of the samples, the percentage above 4 nm is less than 15%. This higher polydispersity 
can readily be observed in the plot as the slope of the curve is lower for GNP.OH than for the rest 
of the particles. Size distribution plots from the different GNP shown as both total counts and 
relative count (%) can be seen in Supporting Information (Figure S 2). 
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Figure 5. Size distribution of samples of gold nanoparticles GNP.OH (n=199), GNP.OH/COOH 
(n=583), GNP.AEBSF (n=2809), GNP.antiKLK5 (n=811), and GNP.COOH AEBSF (n=1778), 
expressed as a comparative view in relative counts (%).  
 
LDI-TOF mass spectrometry 
The successful covalent functionalization was proven by Laser Desorption Ionization – Time of 
Flight Mass Spectrometry (LDI-TOF MS), by analyzing both GNP.COOH AEBSF and 
GNP.AEBSF in negative mode. For GNP.AEBSF, peaks observed at m/z 551 and 566, 
correspond to the AEBSF molecule covalently bonded through an amide linker to the polyethylene 
glycol spacer, fragments including six ethylene glycol units and either a two- or three-carbon chain 
respectively. These results show the effectiveness of the strategy for covalent functionalization. 
For GNP.COOH AEBSF, peaks observed at m/z 551 and 200 and 159 correspond to fragments 
of AEBSF molecule, while peaks observed at m/z 177 and 103 correspond to carboxyl-terminated 
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ethylene glycol fragments. As expected, no peaks indicating a covalent functionalization of 
AEBSF were found (See Supporting Information, Figure S 3 and Figure S 4). 
Thermogravimetric analysis (TGA) 
Thermogravimetric analyses were performed with GNP.OH/COOH, GNP.AEBSF, 
GNP.antiKLK5, GNP.COOH AEBSF and AEBSF·HCl in solution, observing mass 
degradations corresponding to the thiol/drug/antibody with which they are functionalized, and 
confirming the successful functionalization. The sample containing only the drug AEBSF·HCl in 
solution shows a mass loss between 200-400 ºC, corresponding to the drug degradation. In the case 
of GNP.AEBSF, significant mass losses were observed also between 200 – 400 ºC, corresponding 
to big amounts of drug in the sample. In the case of GNP.antiKLK5, the mass loss in this range 
of temperatures was much smaller, suggesting that the percentage of surface functionalized on 
these particles is much less than on those small-drug-functionalized particles (See Supporting 
Information, Figure S 5 -Figure S 9). The sample containing GNP.COOH AEBSF also shows a 
mass loss around 300 ºC, corresponding to the drug. In this case, the biggest mass loss observed 
around 100 ºC corresponds to high amounts of water, indicating the sample was not as dry as the 
rest of the particle samples. Therefore, the smaller mass loss at 300 ºC as compared to 
GNP.AEBSF does not mean a smaller proportion of drug in the sample, but only a higher water 
content. Thiolated-PEG molecules were not completely degraded at the temperatures reached (950 
ºC), as seen by the lack of a mass stabilization of the sample, for which the total mass of them 
cannot be known.  
Dynamic Light Scattering (DLS) 
GNP.OH/COOH, GNP.COOH AEBSF, GNP.AEBSF and GNP.antiKLK5 nanoparticles 
were analyzed by DLS to assess their hydrodynamic diameters, their polydispersity, and whether 
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they are aggregated or monodisperse in solution. The diameters observed are higher than the gold 
core diameters observed by TEM, as hydrodynamic diameter not only considers the core but also 
reflects the chemical functionalization. Hydrodynamic diameters observed are quite similar in all 
particles under study. GNP.OH/COOH showed the highest diameter average as also the highest 
dispersity (12.9±2.7 nm), suggesting these particles are aggregated in solution. The 
electrostatically functionalized particles GNP.COOH AEBSF showed the smallest hydrodynamic 
diameter (7.4±1.2 nm), while particles covalently functionalized with AEBSF (GNP.AEBSF) or 
with antibody (GNP.antiKLK5) showed an increase in their diameter (8.2±2.3 nm and 11.7±2.1 
nm respectively). The sizes observed in the different samples can only be used as an estimation of 
the size and polydispersity of the particles, in accordance with the sensibility of the technique (See 
Supporting Information, Table S 1). 
Based on the results of the different techniques concerning particle sizes, a schematic 
representation of the nanoparticles, the different functionalizations, and their sizes is shown in the 
Supporting Information (Figure S 10). 
 
In vitro inhibition of KLK5 
As a first step, in vitro enzymatic assays were performed to test whether the different kinds of 
nanoparticles functionalized with serine protease inhibitors can inhibit KLK5 activity. 
Experiments were performed following the protocol described by the supplier.27 For activity 
assays, KLK5 was incubated with a specific fluorogenic substrate in the absence or presence of 
the different functionalized nanoparticles (GNP.COOH AEBSF, GNP.AEBSF, 
GNP.antiKLK5), as well as with the free drug AEBSF·HCl or the anti-KLK5 antibody for 
comparison. GNP.OH and GNP.OH/COOH were used as controls. In Figure 6, the percentage 
of inhibition calculated for each type of drug/particles was plotted against the concentration of 
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functional groups responsible for such inhibition (“active groups”). In GNP.OH/COOH, the term 
“active groups” refers to the concentration of PEG.COOH molecules. Likewise, it refers to those 
PEG.COOH molecules after functionalization in case of GNP.COOH AEBSF, GNP.AEBSF, 
and GNP.antiKLK5. Moreover, it represents the concentration of drug in case of GNP.COOH 
AEBSF, GNP.AEBSF and free AEBSF·HCl. As GNP.OH is only coated with one type of thiolate 
with hydroxyl terminated groups, concentration was adjusted to correctly represent an equivalent 
concentration of total thiolates than in GNP.OH/COOH taking in account the proportion of 
PEG.OH to PEG.COOH ligands. This adjustment was also taken into account in the rest of 
experiments. In case of GNP.antiKLK5 and anti-KLK5 in solution, the concentration of anti-
KLK5 antibody is also shown in the axis. A broad range of concentrations was chosen in order to 
determine whether the inhibition follows a certain model. The best fitting model was obtained for 
each kind of particles/drug/antibody and the IC50 values (the concentration at which 50% of 
enzymatic activity is obtained) were estimated. However, it is important to note that these in vitro 
conditions are expected to be different than those inside the cells, including the concentration of 
KLK5 enzyme; for which IC50 values are not expected to be the same in cells and are calculated 
only for comparison purposes. 
 
 S15 
 
 
Figure 6. In-vitro enzymatic inhibition of KLK5 in presence of different gold nanoparticles at 
different concentrations. aConcentration of active groups for GNP and AEBSF·HCl in solution 
(µM). bConcentration of anti-KLK5 antibody in GNP and in solution (pg/mL).cConcentration of 
anti-KLK5 antibody in solution (µg/mL). Values were expressed as Mean±SD (n=3). GNP.OH 
Followed a Boltzmann Sigmoidal model, while the rest of the particles and drugs followed a One 
Phase Exponential Association model  
 
Results in Figure 6 show that the different particles/drug/antibody can actually inhibit KLK5 
activity, although at different concentrations or following a different model. Equations, IC50 values 
and other inhibition parameters obtained can be seen in Supporting Information (Table S 2). 
 
 
 
As expected, AEBSF·HCl in solution inhibits KLK5 activity, which could be attributed to the 
covalent attachment of the fluorosulphonyl group from the drug to the hydroxyl group of the serine 
Concentration
Active groups (µM)a
E
n
z
y
m
a
ti
c
in
h
ib
it
io
n
(%
)
Anti-KLK5 Ab (pg/mL)b143 285 713428 570 1140 1710
Anti-KLK5 Ab (µg/mL)c
 S16 
 
in the enzyme’s active site, and thus being an irreversible inhibition. Interestingly, also control 
particles (GNP.OH and GNP.OH/COOH) display KLK5 inhibitory activity, suggesting a 
possible interaction between the GNP and the enzyme’s active site, for example, the formation of 
hydrogen bonds or ionic bonds. These interactions might therefore affect the normal enzymatic 
activity.  
GNP.OH showed a very different inhibitory behavior than the rest, following a Boltzmann 
Sigmoidal model, and providing much less inhibition as compared by the IC50 values (P<0.001). 
In contrast, GNP.OH/COOH and the rest of the particles or free drug, followed a One Phase 
Exponential Association model, reaching inhibitions higher than 80%. No significant differences 
(P>0.05) were obtained between the inhibitory activity of the particles GNP.OH/COOH, 
GNP.AEBSF, GNP.COOH AEBSF, GNP.antiKLK5 or the free AEBSF.HCl; however, when 
the drug is ionically bonded in GNP.COOH AEBSF, a slight enhancement of the inhibition can 
be appreciated, which could be due to the non-covalent nature of the attachment, which permits 
some drug release, and therefore both the drug and the nanoparticles contribute to the overall 
inhibition. Statistical analysis can be seen in Supporting Information (Table S 4). 
Finally, the free anti-KLK5 did not show inhibitory activity at similar concentrations as when it 
is in GNP.antiKLK5 (50 – 1200 pg/mL). This can be explained as the molar concentration of 
KLK5 in the assay is almost one million times higher than the concentration of antibody. However, 
when the concentration of antibody is increased (1 – 20 µg/mL), inhibition is achieved, which also 
follows an exponential behavior. These results show that the interaction between the anti-KLK5 
antibody and the enzyme can actually inhibit the enzymatic activity, and which, to our knowledge, 
was not previously reported. 
Internalization of GNPs in human keratinocytes  
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To test the ability of gold nanoparticles to be internalized in human keratinocytes (HaCaT), 
GNP.OH/COOH nanoparticles were labelled with the fluorophore BODIPY by covalently 
bonding the fluorophore to the carboxylic acid groups forming an amide bond. Labelled particles 
were added to keratinocytes at a concentration of 30 µM of active groups. After 24 hours of 
incubation at 37ºC, internalization of nanoparticles was visualized by confocal fluorescence 
microscopy (Figure 7). As expected, no red signal was observed in non-treated control cells. In 
contrast, BODIPY-labelled nanoparticles were visualized in the cytoplasm of HaCaT cells 
incubated at 37ºC. Remarkably, the area of the nucleus is observed completely dark, showing that 
the particles do not enter the cell nucleus, for which they should not induce damage to DNA. 
The cell internalization of drugs or proteins is hampered by their physicochemical properties; 
therefore, these particles could be used as an intracellular delivery system. For example, the 
potential use of anti-KLK5 antibody to block KLK5 in vivo, is hampered by the inability of 
antibodies to enter the target cells, as it is known that the cell membrane represents a non-
permissive barrier for the transport of antibodies across it. Therefore, as it is the case of 
GNP.antiKLK5, these nanoparticles could be used to drive cellular uptake of antibodies and target 
cytosolic KLK5 in HaCaT cells. 
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Figure 7. Internalization of BODIPY-labeled GNP.OH/COOH in HaCaT keratinocytes by 
confocal fluorescece microscopy.  HaCaT cells were incubated for 24 hours with 30 µM of 
GNP.OH/COOH. Images show cell membranes counterstained with wheat germ agglutining-
Alexa-594 (green) and internalized BODIPY-labelled particles (red). Analysis was performed in 
a Leica TCS SP5 laser scanning confocal spectral microscope with 63x oil immersion objective 
lens, and images were captured with a Nikon color camera (16 bit). Scale bar: 20 µm. 
 
Cytotoxicity assays 
Although it is generally accepted that the toxicity of gold nanoparticles is low because of the 
low reactivity of the material, there is a growing interest in the study of their toxicity and life 
expentancy. It has been seen that the size of the gold nanoparticles influences the cytotoxicity, 
being the ones with a gold core diameter smaller than 2 nm the ones that present unusual reactivity 
in terms of oxidative stress;28–30 however, toxicity is highly dependent on the outer 
functionalization of the GNP, and PEG entities relieve nanotoxicity and permit the GNP escaping 
the opsonization process in the immune response.31 Hence, the cellular toxicity in human 
keratinocytes (HaCaT cells) was evaluated after incubation with the different nanoparticles by 
performing the MTT assay.  
Control HaCaT + GNP
Membrane GNP Merged
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Cell viability of HaCaT keratinocytes was evaluated both in presence or absence of the glucan 
related zymosan, with the aim of setting up a cellular model that mimics Rosacea conditions, and 
since it is known that zymosan can activate the TLR-2 receptors, whose signalling pathway is 
involved in Rosacea-associated overexpression of KLK5 (see Figure 1),6,7,9 The results show that 
zymosan shows no cytotoxicity after 24 h incubation. Moreover, a possible indirect influence of 
zymosan in cell viability after incubation with nanoparticles was evaluated by incubating HaCaT 
cells with GNP.OH/COOH, both in presence and absence of zymosan, showing also that zymosan 
has no influence on viability results (data not shown). For these reasons, the cell viability in human 
keratinocytes (HaCaT cells) was evaluated under Rosacea conditions (zymosan-stimulated) after 
incubation with the different nanoparticles at concentrations up to 100 µM (GNP.OH, 
GNP.OH/COOH, GNP.COOH AEBSF, GNP.AEBSF, and GNP.antiKLK5), as well as with 
the free drug AEBSF·HCl or the anti-KLK5 antibody (Figure 7). GNP concentrations were 
calculated on the basis of “active groups”. In GNP.OH/COOH the term “active groups” refers to 
the concentration of PEG.COOH molecules. Likewise, it refers to those PEG.COOH molecules 
that were functionalized in case of the other nanoparticles, namely GNP.COOH AEBSF, 
GNP.AEBSF, and GNP.antiKLK5. As GNP.OH does not have two types of thiols, concentration 
was adjusted to correctly represent an equivalent concentration of total thiols than in 
GNP.OH/COOH taking into account the proportion of PEG.OH to PEG.COOH thiols.  
GNP.OH did not cause toxicity in keratinocytes since cell viability was close to 100% at all the 
concentrations tested (Figure 7 A). These results were consistent with the reported alleviation of 
GNP toxicity by PEG functionalization. However, incubation with GNP.OH/COOH resulted in 
a significant decrease in cell viability, around 30% at concentrations above 5 µM (Figure 7 B). 
This effect could be attributed to the reactivity of free COOH groups on the surface of these 
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nanoparticles, prior to the functionalization with the desired drugs. Despite the toxicity levels 
observed with these particles, they should not represent a problem when the administration route 
is intended to be dermal, as the replication of keratinocytes in the skin occurs faster than the 
majority of cells in the organism, and the outer layer of the skin (stratum corneum) is entirely 
comprised of biologically dead cells. 
In contrast, the serine protease inhibitor AEBSF·HCl was highly cytotoxic in solution, resulting 
in less than 10% of cell viability at 75 µM and undetectable cell viability levels at 100 µM, which 
completely impairs its potential therapeutic use. This high toxicity is most probably related to the 
reactivity of the fluorosulphonyl group, which might be interacting with other vital biomolecules 
of the cell. However, drug associated cytotoxicity was significantly reduced (p<0.05) when 
AEBSF is linked to the GNP through an electrostatic bond (GNP.COOH AEBSF), and especially 
through a covalent bond (GNP.AEBSF). (Figure 7 C). The higher cytotoxicity observed for the 
electrostatically-bound AEBSF nanoparticles is therefore related to the expected dissociation of 
the drug at the cell culture conditions (aqueous solution, pH 7.4). These particles thus represent a 
great potential as a delivery system for highly cytotoxic drugs, as they could promote 
internalization while reducing drug-associated toxicity. 
Incubation with GNP.antiKLK5 at concentrations up to 100 µM active groups (285 pg/mL 
antibody), modestly decreased cell viability to 80%. In contrast, incubation with the anti-KLK5 
antibody did not cause any cytotoxic effect at equivalent antibody concentrations. (Figure 7 D), 
and up to 1000 pg/mL of antibody (data not shown). This effect could be attributed to the presence 
of unreacted COOH groups on the GNP surface; however, the cell viability values are significantly 
higher with the attached antibody as compared to the nanoparticles alone (GNP.OH/COOH) 
(P<0.05) (Figure 7 E). 
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Figure 7. Cell viability of HaCaT keratinocytes after incubation for 24 hours with GNPs at 
different concentrations of active groups (µM). Cell viability was assayed by the MTT reduction 
method and expressed as percentage of zymosan treated control cells (dotted line). Values 
represent the Mean ± SD (n=3) (* P<0.05, versus zymosan-treated control cells; # P<0.05, versus 
cells treated with AEBSF·HCl in solution). (A) GNP.OH, (B) GNP.OH/COOH, (C) 
GNP.COOH AEBSF and GNP.AEBSF, and (D) GNP.antiKLK5. In panels (C) and (D) free 
drug AEBSF.HCl and anti-KLK5 antibody are included respectively for comparison. In panel (D) 
the concentration of antibody (pg/mL) is also shown. (E) Comparison of cell viability among 
different particles/drug/antibody after 24 h incubation at 100 µM concentration of active groups. 
Different letters indicate significant differences between groups (P<0.05). 
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Inhibition of the inflammatory response in human keratinocytes 
As it has been reported that TLR-2 receptor expressed in HaCaT keratinocytes can be activated 
by zymosan, we sought to evaluate the inflammatory response in HaCaT cells upon 24 h incubation 
with this glucan molecule (100µg/mL), with the aim of mimicking Rosacea conditions. Incubation 
with zymosan simulated the inflammation observed in Rosacea patients, as cells without any 
stimulation showed basal IL-8 levels (893 ± 78 pg/mL), while cells incubated with zymosan 
secreted 15 times more IL-8 (up to 14460 ± 1150 pg/mL) (P<0.05). 
Thus, the potential of the different GNP to inhibit the inflammatory response was assessed 
through quantification of secreted IL-8 in zymosan-stimulated HaCaT cells. Hence, keratinocytes 
were incubated with zymosan for 24 h in presence of the different GNP at different concentrations 
of active groups (0.625 µM to 100 µM). Levels of secreted IL-8 were quantified and plotted as 
percentage respect to the positive and negative controls versus concentration of active groups 
(Figure 8). 
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Figure 8. (A-D) IL-8 secretion in HaCaT incubated with the different nanoparticles at different 
concentrations of active groups. (D) Concentrations of anti-KLK5 antibody in GNP.antiKLK5 
are also shown in the axis. (E) Comparison of IL-8 levels after incubation with different particles 
at 100µM. Different letters represent significant differences (P<0.05). All results are plotted 
relative to zymosan-stimulated cells and non-stimulated cells. Values represent Mean±SD (n=3).  
 
Incubation with GNP.OH diminished only slightly, the levels of the pro-inflammatory IL-8, 
even at the highest concentrations tested, which is probably related to their low enzymatic 
inhibitory activity. In contrast, GNP.OH/COOH, GNP.AEBSF, and GNP.antiKLK5 
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observed with GNP.COOH AEBSF, which showed an increase of IL-8 secretion at 
concentrations below 30 µM, but a decrease to undetectable levels above this concentration. 
Inhibition of intracellular KLK5 in human keratinocytes 
The potential of the functionalized nanoparticles to inhibit KLK5 activity ex vivo was evaluated 
under simulated Rosacea conditions. Hence, we measured the intracellular KLK5 activity in non-
stimulated and in zymosan-stimulated keratinocytes. Also, cells were incubated with zymosan in 
presence of GNP.COOH AEBSF, GNP.AEBSF, GNP.antiKLK5, and GNP.OH/COOH as a 
control. In zymosan-stimulated keratinocytes (Control(+)), KLK5 activity was increased by 21% 
compared to the basal activity value in non-stimulated cells (Control(-)) (Figure 9). In this case, 
data did not reach statistical significance due to the wide variations in measurements. When 
zymosan-stimulated cells were simultaneously treated with the nanoparticles (100 µM of active 
groups), KLK5 activity was importantly reduced. GNP.COOH decreased the intracellular KLK5 
activity reaching very similar levels to those of untreated cells (Control(-)), but particles further 
functionalized (GNP.COOH AEBSF, GNP.AEBSF and GNP.antiKLK5) significantly 
decreased activity by 35-40 % (P<0.01), reaching levels even below the basal value.  
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Figure 9. Intracellular KLK5 enzymatic activity of zymosan-stimulated HaCaT cells incubated 
with nanoparticles at 100 µM active groups (GNP.COOH AEBSF (n=3), GNP.AEBSF (n=4), 
GNP.antiKLK5 (n=4) or GNP.OH/COOH (n=7)). Control(-): non-stimulated cells without 
nanoparticles (n=7). Control(+): Zymosan-stimulated cells without nanoparticles (n=7). KLK5 
activity is expressed as percentage of non-stimulated Control(-) cells. Values represent Mean ± 
SD. **Differences with statistical significance (P<0.01) versus Control(+). 
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AEBSF molecules attached to GNP.AEBSF. This would imply that antibody-functionalized 
nanoparticles have a higher efficacy than AEBSF-functionalized nanoparticles, something that 
could be explained because of the high specificity of the anti-KLK5 antibody towards KLK5 
enzyme. Nonetheless, other unknown factors, such as the stability of the nanoparticles in the cell 
medium, may also influence their efficacy. 
 
 
 
Figure 10. Comparison of the different particles in terms of cell viability (%), inhibition 
of in vitro KLK5 activity (%), inhibition of intracellular KLK5 activity (%) and inhibition 
of IL-8 secretion (%). N.A.: Not assayed. aInhibition values respect to Zymosan-
stimulated HaCaT cells. Values in the bars represent the Means, values on the right of 
the bars represent one standard deviation. 
 
Conclusions  
Water soluble monodisperse gold nanoparticles were synthesized, comprised of a gold core (ca. 
1.5 nm diameter) and coated with a mixture of thiolated-PEG linkers of sufficient length that 
particles with hydrodynamic diameters around 10 nm (GNP.OH/COOH) are obtained, which 
were functionalized using the carboxyl terminal group on their surface. To explore the application 
of these GNP as delivery vehicles for drugs targeting key proteins altered in Rosacea, we 
immobilized the serine protease inhibitor AEBSF·HCl (either covalently or electrostatically) or 
the anti-KLK5 antibody (covalently). After functionalization, particles remain highly-water 
soluble giving no signs of aggregation as observed by TEM and DLS.  
GNP (100 µM active groups)
In vitro  KLK5 activity inhibition (%) 19 ±5 66 ±8 95 ±1 72 ±2 79 ±6
Cell viability (%)a 95 ±1 58 ±1 45 ±14 64 ±1 78 ±3
IL-8 secretion inhibition (%)a 22 ±1 70 ±2 100 ±2 75 ±2 81 ±9
Intracellular KLK5 activity inhibition (%)a N.A. 16 ±14 35 ±17 38 ±6 40 ±13
GNP.anti KLK5GNP.OH GNP.OH/COOH GNP.COOH AEBSF GNP.AEBSF
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GNP.OH nanoparticles did not cause toxicity in keratinocytes since cell viability was close to 
100% at all the concentrations tested, but a decrease in cell viability was observed with mixed 
hydroxyl/carboxyl functionalized gold nanoparticles (GNP.OH/COOH), an effect that may be 
attributed to the reactivity of free COOH groups on the surface of these nanoparticles. However, 
the most remarkable observation is that although the drug AEBSF·HCl in solution is highly 
cytotoxic, its incorporation to the nanoparticles through electrostatic, but especially through 
covalent bonding, significantly reduces its cytotoxicity, showing the high potential of the GNP to 
be used as drug delivery systems for highly cytotoxic drugs, as the complexation can increase drug 
safety. In the case of GNP.antiKLK5, the modest levels of toxicity observed are most probably 
related to the unreacted COOH groups remaining on the GNP surface. On this basis, we may 
speculate that a future chemical modification of these particles could lead to an increase in their 
safety, if after antibody attachment to the nanoparticles, the remaining COOH groups are blocked 
with other molecules, with the aim to create a non-toxic GNP surface, yet maintaining their high 
water solubility. 
Drug- and antibody-functionalized particles, but remarkably, also GNP.OH/COOH particles 
without any further functionalization, inhibited in vitro KLK5 activity, in a similar way as the 
serine protease inhibitor AEBSF·HCl in solution.  
Confocal fluorescence microscopy showed that BODIPY-labeled GNP.OH/COOH particles 
can be successfully internalized in HaCaT keratinocytes, and therefore the impairment of 
antibodies, other peptides, or drugs, to enter the target cells could be counteracted by their binding 
to these GNP.  
This work provide evidence that GNP functionalized with a serine protease inhibitor either 
electrostatically (GNP.COOH AEBSF) or covalently (GNP.AEBSF), or with an anti-KLK5 
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antibody (GNP.antiKLK5) can target cytosolic KLK5, reduce its enzymatic activity, and 
significantly decrease IL-8 secretion HaCaT cells stimulated with zymosan, therefore being a 
suitable delivery system in the treatment of Rosacea through this novel therapeutic strategy in the 
disease. Despite the efficacy of GNP.COOH AEBSF for inhibiting KLK5 both in vitro and 
intracellularly, as well as for decreasing the secretion of IL-8, their drug-associated cytotoxicity 
may compromise their future use. Instead, according to their high efficacy and safety, 
GNP.AEBSF and GNP.anti KLK5 are probably the most promising options for a future treatment 
of the disease.  
Moreover, the versatility of these particles permits linking them with different drugs, antibodies 
or other peptides, and hence their capability for being internalized in keratinocytes, and for 
diminishing the toxicity of the attached drugs, makes them promising drug delivery systems in 
other skin diseases as well.  
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Experimental Section 
Materials 
Chemicals: All reagents were of analytical grade. Gold(III) chloride trihydrate, 
tetraoctylammonium bromide, sodium borohydride, N-hydroxysuccinimide (NHS), N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), phosphate buffered saline 
(PBS) tablets, Trizma® base, MES monohydrate, Dulbecco′s Modified Eagle′s Medium (DMEM), 
Zymosan A from Saccharomyces cerevisiae, hydrochloric acid (reagent grade 37%), and sodium 
hydroxide (pellets EMPLURA®), and thiazolyl blue tetrazolium bromide (MTT) were purchased 
from Sigma-Aldrich (Germany). Sodium phosphate monobasic was purchased from Panreac 
(Spain). 4,4-Difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid, succinimidyl 
ester (BODIPY® FL) was purchased from from Setareh Biotech Eugene (USA). 
   Functionalized thiols HS-(CH2)11-(O-CH2-CH2)6-O-CH2-COOH (PEG.COOH) and HS-
(CH2)11-(O-CH2-CH2)6-OH (PEG.OH) were purchased from Prochimia (Poland). 4-(2-
Aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF·HCl) was purchased from Fisher 
Scientific (USA).  
Recombinant Human Kallikrein 5 and Fluorogenic Peptide Substrate BOC-Val-Pro-Arg-AMC, 
were purchased from R&D systems, (USA). 
4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), MEM Non-Essential Amino 
Acids Solution (100X), penicillin, streptomycin, Fetal Bovine Serum (heat inactivated), and IL-8 
Human ELISA Kit, were purchased from Thermo Fisher Scientific (Life Technologies) (USA).  
Solvents and buffers: Water 18Ω grade was always used, obtained from a Millipore MilliQ 
equipment. Dimethyl sulfoxide (DMSO) was purchased from Sigma (Germany). PBS buffer was 
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prepared and used at a concentration of 10 mM as specified by provider. MES buffer was prepared 
using MES monohydrate at 100 mM concentration and adjusted to pH 5.5 with 0.1 M sodium 
hydroxide solution. Dulbecco′s Modified Eagle′s Medium (DMEM) was prepared as specified by 
provider. Enzymatic assay buffer was prepared using sodium phosphate monobasic at a 
concentration of 100 mM and adjusted to pH 8 with 0.1 M sodium hydroxide solution. TRIS buffer 
was prepared using Trizma base at a concentration of 0.86 M and adjusted to pH 7 with 0.1 M 
hydrochloric acid solution. 
Filtration materials: Dialysis Membrane was a Regenerated Cellulose Tubular Membrane 
purchased from Cellu-Sep. Vivaspin 500 tubes with polyethersulfone membrane (100 MWCO) 
were purchased from Sartorius (Germany). Millex-GP syringe filters (polyether sulphone, 0.22 µm 
pore size) were purchased from Merck Millipore (Germany). 
 
Methods 
Synthesis and functionalization of gold nanoparticles 
GNP were detected in aqueous solution by the observation of a red-violet color and the presence 
of a characteristic SPR band near λ=515 nm using a UV-1800 Shimadzu UV spectrophotometer 
(See Supporting Information, Figure S 1). 
 
Synthesis of hydroxyl gold nanoparticles (GNP.OH): 
Gold(III) chloride trihydrate (35.5 mg, 90 μmol) was dissolved in water (1 mL) and set under 
magnetic stirring at room temperature. A solution of tetraoctylammonium bromide (125 mg, 410 
μmol) in toluene (2 mL) was added to the gold solution. An orange emulsion was formed. 
Subsequently, a solution of PEG.OH (7.3 mg, 15.6 μmol) in water (0.6 mL) was added to the 
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solution. Finally, a solution of sodium borohydride (30 mg, 793 μmol) in water (1 mL) was added 
dropwise along 5 min to form a violet solution during the addition. Stirring was kept for 3 hours 
at room temperature, and after that, GNP were partitioned with further addition of toluene (2 mL) 
and water (2 mL) to favor phase separation. The organic phase was extracted with water (2 x 2 
mL). The aqueous solution of GNP was dialyzed in water for 120 hours, replacing the water in the 
medium once daily.  
 
Synthesis of hydroxyl-carboxyl gold nanoparticles (GNP.OH/COOH): 
Gold(III) chloride trihydrate (67 mg, 170 μmol) was dissolved in water (2.5 mL) and set under 
magnetic stirring at room temperature. A solution of tetraoctylammonium bromide (125 mg, 410 
μmol) in toluene (5 mL) was added to the gold solution. An orange emulsion was formed. 
Subsequently, a solution of PEG.OH (6.9 mg, 14.7 μmol) in water (0.5 mL) and a solution of 
PEG.COOH (6 mg, 11.4 μmol) in water (0.5 mL) were added to the solution in order to have a 
mixture of two different thiols on the surface of the GNP. Finally, a solution of sodium borohydride 
(33.3 mg, 880 μmol) in water (2.5 mL) was added dropwise along 5 min to form a violet solution 
during the addition. Stirring was kept for 4.5 hours at room temperature, and after that, GNP were 
partitioned with further addition of toluene (2 mL) and water (2 mL) to favor phase separation. 
The organic phase was extracted with water (2 x 2 mL). The aqueous solution of GNP was dialyzed 
in water for 96 hours, replacing the water in the medium once daily.  
 
Ionic functionalization of gold nanoparticles with AEBSF (GNP.COOH AEBSF) 
An aliquot of GNP.OH/COOH corresponding to 0.7 µmol of PEG.COOH was washed under 
centrifugation-resuspension cycles using Vivaspin centrifugal filter tubes (0.5 mL of sample per 
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tube) with enzymatic assay buffer (2 x 0.5 mL). Particles were finally resuspended in 200 µL of 
the same buffer. Afterwards, a solution of AEBSF·HCl (167 µg, 0.7 µmol) dissolved in assay 
buffer (150 µL) was added to the reaction. The final concentration of both PEG.COO and 
AEBSF·HCl was estimated to be 2 mM. The mixture was kept under vortex stirring for 10 min at 
room temperature in order to assure interaction of AEBSF·HCl molecules with carboxylate groups. 
GNP were always used freshly prepared.  
 
Covalent functionalization of gold nanoparticles with AEBSF (GNP.AEBSF) 
An aliquot of GNP.OH/COOH corresponding to 0.7 µmol of PEG.COOH was washed under 
centrifugation-resuspension cycles using Vivaspin centrifugal filter tubes (0.5 mL of sample per 
tube) with TRIS buffer pH 7 (2 x 0.5 mL). Particles were resuspended in 1 mL of the same buffer 
in order to assure the pH of the medium for the reaction. A solution of NHS (14 mg, 130 µmol) 
and EDC (4 mg, 20 µmol) in TRIS buffer pH7 (0.2 mL) was added to the GNP and the sample 
was kept under vortex stirring at room temperature for 0.5 hours to activate all the carboxyl groups. 
Afterwards, a solution of AEBSF·HCl (7 mg, 29 µmol) in TRIS buffer (0.2 mL) was added to the 
reaction and stirring was kept for 3 hours. Particles were washed under centrifugation-redissolution 
cycles using Vivaspin centrifugal filter tubes (0.5 mL of sample per tube) with 100 mM MES 
buffer pH 5.5 (4 x 0.5 mL) to remove non-bound AEBSF·HCl, NHS and EDC, and to adjust the 
pH to acidic conditions. Particles were resuspended in 100 mM Phosphate pH 7 to a final volume 
of 350 µL just before use (final concentration of PEG.AEBSF was estimated to be 2 mM). 
 
Covalent functionalization of gold nanoparticles with anti-Kallikrein 5 antibody 
(GNP.antiKLK5) 
 S33 
 
An aliquot of GNP.OH/COOH corresponding to 0.7 µmol of PEG.COOH was washed under 
centrifugation-resuspension cycles using Vivaspin centrifugal filter tubes (0.5 mL of sample per 
tube) with TRIS buffer pH 7 (2 x 0.5 mL). Particles were resuspended in 1 mL of the same buffer 
in order to assure the pH of the medium for the reaction. A solution of NHS (14 mg, 130 µmol) 
and EDC (4 mg, 20 µmol) in TRIS buffer pH7 (0.2 mL) were added to the GNP and sample was 
kept under vortex stirring at room temperature for 0.5 hours to activate all the carboxylic acid 
groups.  
Afterwards, a solution of anti-Kallikrein 5 antibody (2 µg) in 20 mM TRIS buffer pH 7 with 138 
mM NaCl (0.2 mL), was added to the reaction and stirring was kept overnight at room temperature. 
Particles were washed under centrifugation-resuspension cycles using Vivaspin filter tubes (0.5 
mL samples) with 10 mM Phosphate buffer saline pH 7.4 (4 x 0.5 mL). Particles were resuspended 
in enzymatic assay buffer (100 mM Phosphate pH 7) to a final volume of 350 µL (final 
concentration of PEG.antiKLK5 + PEG.COOH 2 mM). 
 
Water solubility and long-term stability of GNP 
The water solubility of GNP was screened by centrifuging the aqueous solution of GNP at the 
original concentration, using 1 mL Eppendorf tubes, at 16500g for different times, while observing 
the sedimented pellet. A high-water solubility was considered when, after 30 min centrifugation 
at 16500g, a pellet of GNP could barely be observed, while leaving the supernatant of a similar 
color to the naked eye as before centrifugation. Aggregation of GNP was assessed by observing 
the occurrence of a shift to higher wavelength on the SPR band using UV-VIS spectroscopy. 
Spectra were recorded from freshly prepared GNP and one year after being synthesized. 
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Size and concentration of gold nanoparticles 
The extinction coefficient, concentration and size of GNP were estimated using UV-VIS 
absorption spectroscopy according to previously reported protocols.22 As the thiolated-PEG 
molecules are the stabilizing agents of the GNP, their complete bond to them was assumed. 
Therefore, the proportion of PEG.COOH to PEG.OH molecules in GNP.OH/COOH and in 
subsequent functionalizations was assumed to be 1:1.3. The number of thiol molecules attached 
per nanoparticle was estimated by dividing the calculated concentration of thiol molecules into the 
calculated concentration of GNP.  
 
 
Microscopy  
Transmission Electron Microscopy (TEM) was performed using a Tecnai SPIRIT (FEI Co.) 
electronic microscope at 120 kV from the Centres Cientifics i Tècnològics de la Universitat de 
Barcelona (CCiTUB). Samples were analyzed by placing 5 µL of nanoparticles (GNP.OH, 
GNP.OH/COOH, GNP.AEBSF and GNP.antiKLK5) at a concentration of 4 mM of thiolated-
PEG molecules on a carbon-coated copper grid. The images were captured by a Megaview III 
camera and digitalized with the iTEM program. The size of the GNP gold core was measured with 
the Analysis software (ImageJ®) using the particle-count tool. 
 
LDI-TOF Mass spectrometry 
Laser desorption/ionization time-of-flight mass spectrometry (LDI-TOF-MS) analysis was 
performed using a 4800 Plus MALDI TOF/TOF (ABSciex - 2010) mass spectrometer, without 
matrix assistance, equipped with a solid state laser (Nd:YAG) (355 nm, frequency 200 Hz, pulse 
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3-7 ns), and a Time of Flight analyzer in Reflective mode, at the CCiTUB. Analyses were 
performed in negative mode. 
 
Thermogravimetric analysis (TGA) 
Thermogravimetric analyses were performed on a Mettler-Toledo TGA-851e thermobalance at 
the CCiTUB. Experimental conditions: alumina crucibles of 70 µL volume, atmosphere of dry 
nitrogen with 50 mL/min flow rate, heating from 30 ºC to 1000 ºC with a heating rate of 10 ºC/min. 
A blank curve has been previously performed and it has been subtracted. 
 
 
Dynamic light scattering (DLS) 
The average hydrodynamic diameter of GNP was determined through dynamic light scattering 
(DLS), using a Zetasizer Nano ZS, Malvern Instruments, Malvern, UK. The different GNP were 
diluted at different concentrations using 2 mM PBS, and all samples were filtered using 2 µm pore 
size syringe filters. At least three independent samples of each kind of nanoparticles were analyzed, 
performing 32 measurements in each analysis. 
 
In vitro enzymatic inhibition of KLK5 
Different functionalized and control GNP, previously washed with and resuspended in assay 
buffer (pH 8) to a concentration of GNP corresponding to 4.6 mM of total thiolated-PEG 
molecules, were tested to inhibit KLK5 activity in solution according to the manufacturer’s 
protocol. KLK5 was diluted to 4 ng/µL, and fluorogenic Peptide Substrate BOC-Val-Pro-Arg-
AMC was diluted to 200 µM, both in assay buffer. 25 µL of KLK5 were added to a fluorescence 
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96-well plate reader. Different amounts of GNP were diluted with assay buffer to a final volume 
of 50 µL and mixed with the KLK5 in the wells. As positive control, 50 µL of assay buffer was 
added to plates with no GNP. Samples were incubated for 15 min under soft vortex stirring and 
enzymatic reaction was started by adding 50 µL of 200 µM fluorogenic Peptide Substrate BOC-
Val-Pro-Arg-AMC to wells, in which the KLK5 cleaves the bond between arginine and the 
fluorophore aminomethyl coumarin (AMC). Immediately, fluorescence emitted by AMC was read 
continuously for 10 min at an excitation/emission of 380 nm/460 nm and plots of fluorescence 
against time were obtained. The slope of the positive control was taken as 100 % enzymatic 
activity. Enzymatic activity of the samples incubated with different concentrations of GNP was 
calculated respect to the positive control. Enzymatic inhibition was obtained by subtracting the 
activity to 100% and plotted against the concentration of functional groups thought to be 
responsible for the inhibition (“active groups”). For GNP.OH/COOH, concentration of active 
groups corresponds to that of PEG.COOH groups, or the corresponding reacted group in the 
subsequent functionalizations (GNP.COOH AEBSF, GNP.AEBSF, GNP.antiKLK5, and 
GNP.COOH brimonidine). As GNP.OH only has one type of PEG.OH groups, the theoretical 
concentration of “active groups” was calculated to correctly represent the same concentration of 
total thiolated-PEG molecules by considering the proportion of the two types of thiolated-PEG 
molecules in GNP.OH/COOH. 
Mathematical models describing the inhibition were obtained and statistical analyses were 
performed using Prism GraphPad software.  
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Cell line and growth conditions 
The human keratinocyte (HaCaT) cell line (ATCC) was routinely grown in high-glucose 
Dubelcco’s Modified Eagle’s medium (DMEM) supplemented with 25 mM hepes, 1% non-
essential amino acids, 100U/mL penicillin, 100 μg/mL streptomycin, and 10% heat inactivated 
fetal calf serum (FCS). Cells were cultured in a humidified incubator at 37⁰C in a 5% CO2 
atmosphere and received fresh medium every 3 days. Experiments were performed at 80-90% of 
confluence (passes between n=85-95). 
 
Internalization of GNPs in human keratinocytes  
HaCaT (2x105 cells/mL) were seeded in 12-wells plates and grown 80-90% of confluence. 
GNP.OH/COOH particles were dyed with BODIPY. Briefly, an aliquot of GNP.OH/COOH 
corresponding to 0.7 µmol of PEG.COOH was washed under centrifugation-resuspension cycles 
using Vivaspin centrifugal filter tubes (0.5 mL of sample per tube) with TRIS buffer pH 7 (2 x 0.5 
mL). Particles were resuspended in 1 mL of the same buffer in order to assure the pH of the 
medium for the reaction. Afterwards, a solution of BODIPY (29 µmol) in DMSO (0.1 mL) was 
added to the reaction and stirring was kept for 3 hours. Particles were washed under centrifugation-
redissolution cycles using Vivaspin centrifugal filter tubes (0.5 mL of sample per tube) with 100 
mM Phosphate buffer pH 7 (4 x 0.5 mL) to remove DMSO and non-bound BODIPY. Particles 
were resuspended in 100 mM Phosphate, pH 7 to a final volume of 350 µL just before use (final 
concentration of total thiolated-PEG molecules was estimated to be 4.6 mM). BODIPY-dyed 
GNPs were added to cells at a concentration of 30 µM of active groups. After 24-hour incubation 
GNP internalization was assessed by confocal fluorescence microscopy. For this, three PBS 1X 
washes (3 x 100 µL) steps were done to remove the non-internalized nanoparticles and the plasma 
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membranes were stained for 30 minutes with 10 µg/ml Alexa Fluor 488-conjugated with 
fluorescent wheat germ agglutinin (WGA), which stains the glycocalyx membrane. Then, cells 
were fixed with 3% paraformaldehyde for 30 minutes, washed with PBS 1X and covered with 
mounting medium (Fluoromount-G). Internalization of GNPs in HaCaT was analysed by laser 
scanning confocal microscopy (Leica TCS SP5), using the 63X oil immersion objective lens. 
Images were taken with a Nikon colour camera (16 bit). The fluorescent excitation wavelengths 
were set to 485 nm (red; BODIPY) and 543 nm (green; membrane). Z-stacks were performed with 
a layer interval of 0.5 µm. Images were analysed using Fiji image software. 
 
MTT assay  
The effect of the different GNPs on cell viability was evaluated using the MTT cytotoxicity 
assay (reduction of tetrazolium salt carried out by intracellular dehydrogenases of viable living 
cells). For this, cells HaCaT (2x105 cells/mL) were plated in 12-wells plates for 24-48h until 80-
90% of confluence and exposed to different types of nanoparticles (GNP.OH, GNP.OH/COOH, 
GNP.COOH AEBSF, GNP.AEBSF, and GNP.antiKLK5 as well as to AEBSF.HCl or anti-
KLK5 antibody in solutionin the presence of 100 µg/ml of zymosan. Several concentrations were 
tested for each type of nanoparticle (1.2-5-10-30-75-100 µM of active groups) starting from a stock 
solution at a concentration of 2 mM active groups. In parallel, a positive control (incubation only 
with zymosan) and a negative control (cells without any stimulation) were processed for 
comparison.  After 24 h incubation, cells were washed with PBS, and further incubated with fresh 
medium in the presence of 10% MTT for 1h. DMSO 99% was added to lyse the cells and dissolve 
the purple insoluble crystals of MTT. The cell lysate was transferred to a 96-well new plate and 
then the absorbance was read using a Microplate Autoreader at λ = 540 nm.  
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Cytokine determination 
HaCaT cells were grown in 12 well plates (2x105 cells/mL) until 80-90% confluency and 
exposed, to the different types of GNP (GNP.OH, GNP.OH/COOH, GNP.COOH AEBSF, 
GNP.AEBSF and GNP.antiKLK5) in the presence of zymosan (100 µg/ml). Different 
concentrations of GNP were tested (1.2-5-10-30-75-100 µM of active groups). HaCaT cells 
stimulated with zymosan without GNP were taken as the positive control, and cells without any 
stimulation as the negative control. Supernatants were collected after 24-hour incubation, 
centrifuged at 16500g for 5 minutes and immediately stored at -80 ⁰C. IL-8 was measured using 
the enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s manual (BD 
Biosciences).  
 
Intracellular KLK5 activity 
Intracellular KLK5-5 was assayed as described27 with few modifications. Briefly, HaCaT 
keratinocytes (2x105 cells/ml) were grown for 24 h on six-well culture plates at 37 ºC in a 5% CO2 
atmosphere. Then, cells were incubated for 24 hours with GNP.OH/COOH, GNP.AEBSF and 
GNP.antiKLK5 at a concentration of 100 µM of active groups, in the presence of zymosan (100 
µg/mL). HaCaT cells stimulated with zymosan without GNP were taken as the positive control, 
and cells without any stimulation as the negative control. After that, cells were washed with cool 
10 mM PBS (3 X 100 µL), scraped and suspended in cool 10 mM phosphate buffer pH 8 (100 µL). 
Samples were lysed through sonication and centrifuged (30 min at 16,000g) to remove cells debris. 
Protein concentration was measured by the method of Lowry.32 The different samples were 
adjusted to equal protein concentration and KLK-5 activity was assayed by monitoring the 
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hydrolysis of the fluorogenic Peptide Substrate BOC-Val-Pro-Arg-AMC following the protocol 
described by the supplier. 27 
 
Statistical analysis 
In in vitro inhibition of KLK5 activity experiments, different regression models were tested 
using GraphPad Prism version 6.0 (GraphPad Software Inc., La Jolla, CA, United States), being 
the Boltzmann Sigmoidal the one that best describes inhibition provided by GNP.OH, while the 
One Phase Exponential Association the one that best describes inhibition in the rest of the particles 
or free drug. 
Boltzmann Sigmoidal model is described by the equation: 
𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 +  
(𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚)
1 + 𝑒
𝑉50−𝑋
𝑆𝑙𝑜𝑝𝑒
 
Where Y is the inhibition (%) at a certain concentration, Top is the maximum inhibition that can 
be achieved, Bottom is the theoretical inhibition at zero concentration, X represents the 
concentration, V50 is the concentration at which half of the maximum inhibition is reached, and 
slope describes the steepness of the curve. 
One Phase Exponential Association model is described by the equation:  
Y = Ymax (1 - e
-kX) 
Where Y represents the inhibition at a certain concentration, Ymax is the maximum inhibition 
that can be achieved, and X represents the concentration.  
Statistical analyses were performed using SPSS version 20.0 software (SPSS, Inc.) and GraphPad 
Prism version 6.0 (GraphPad Software Inc., La Jolla, CA, United States). Data were expressed as 
Mean ± SD, unless stated otherwise. For in vitro KLK5 inhibition, IC50 values were therefore 
obtained according to the corresponding equation and compared. For cytotoxicity studies, 
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comparison between the different groups was performed considering the cell viabilities obtained 
at a concentration of 100 µM of active groups. For anti-inflammatory activity of GNP, IL-8 
secretion levels after incubation with nanoparticles at 100 µM of active groups were compared. 
For the inhibition of intracellular KLK5, enzymatic activity values after incubation of cells with 
GNP at a concentration of 100 µM of active groups were compared. Differences between more 
than two groups were assessed using one-way ANOVA followed by Tukey’s test. Significant 
differences were always established at P ≤ 0.05. 
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